The latest Business updates from the science industry


by Gwyneth Astles Autoclave specialist to drive global service strategy


On 1st August 2025, Priorclave proudly announced the promotion of Ranjit Rai to the position of Service Director. This well-earned advancement marks a signifi cant milestone in a career spanning more than three decades of dedicated service, technical expertise, and global support.


Ranjit Rai fi rst joined Priorclave thirty-four years ago and has since become an integral part of the company’s operations and growth. Since 2016, he has served as Service Manager, demonstrating an unmatched depth of knowledge across the entire Priorclave autoclave range. His understanding of both legacy and current models has been instrumental in maintaining the company’s reputation for reliability, performance, and service excellence.


A key fi gure in Priorclave’s global service network, Ranjit Rai has played a central role in software development and technical training for international service support teams. His hands-on approach and strong commitment to customer satisfaction have taken him around the globe - delivering support and complex repair solutions in countries including Australia, New Zealand, Russia, India, Bangladesh,


Malaysia, Singapore, Indonesia, Canada, the USA, and across Africa.


Ranjit Rai’s extensive familiarity with the earliest generations of Priorclave autoclaves has ensured continued support for pioneering units and helped shape the development of the company’s modern lineup. His insights and experience have had a direct impact on the design, durability, and functionality that defi ne Priorclave’s products today.


In his new role as Service Director, Ranjit Rai brings an unwavering commitment to excellence, an exceptional technical pedigree, and a global perspective on service and support. His leadership will play a key role in advancing Priorclave’s mission to deliver world-class autoclave solutions backed by outstanding technical service.


Priorclave extends its warmest congratulations to Ranjit Rai on this well-deserved promotion and looks forward to the continued innovation and strength he brings to the team.


More information online: ilmt.co/PL/kkAO 65405pr@reply-direct.com


Appointment strengthens cancer and infectious disease research


The Wistar Institute has appointed Simon Chu, PhD, as a Caspar Wistar Fellow in its Ellen and Ronald Caplan Cancer Center, strengthening its focus on data-driven cancer and infectious disease research.


Chu specialises in genomics analysis, creating computational tools and applying machine learning to reveal the genetic underpinnings of disease and uncover new opportunities for drug discovery. His work often centres on transposable elements - so-called ‘jumping genes’ - which can rearrange themselves within the genome and infl uence gene expression in ways that may drive disease.


“Simon brings a powerful dimension to our research,” said Dario Altieri, MD, President and CEO of The Wistar Institute and Director of the Caplan Cancer Center. “By combining advanced algorithms with biological inquiry, he is helping us tackle questions that can only be answered through the integration of deep science and data.”


Simon Chu. Credit: The Wistar Institute Chu’s approach blends computer science, engineering, and biology.


“I ask biological questions, but solve them through engineering,” he explained. “At Wistar, there’s a vibrant community of computational biologists with complementary expertise, which makes it an exciting place to advance interdisciplinary research.”


Chu earned his PhD in computer science and engineering at the University


of Connecticut, following bachelor’s and master’s


degrees in computer science from Beijing University of Chemical Technology. He pursued postdoctoral research with Dr Peter J. Park at Harvard Medical School before joining ROME Therapeutics, where he applied data science to clinical drug discovery.


His appointment refl ects Wistar’s growing commitment to harnessing computational biology as a cornerstone of future breakthroughs in oncology and infectious disease.


More information online: ilmt.co/PL/yMND 65554pr@reply-direct.com


Advisory board appointment advances protein degradation program


PhoreMost has added a heavyweight in drug discovery to its Scientifi c Advisory Board with the appointment of Dr Adam Gilbert, a long-standing leader in medicinal chemistry and targeted protein degradation.


Gilbert, who spent more than three decades at Pfi zer, played central roles in the development of multiple breakthrough therapies, including the recently approved LITFULO™ (ritlecitinib) for alopecia areata, as well as contributions to the ABRYSVO™ RSV vaccine and the COMIRNATY® COVID-19 mRNA vaccine. His career has spanned covalent inhibitors, protein homeostasis modulators, and vaccine antigens - expertise that positions him to help shape PhoreMost’s growing degrader pipeline.


PhoreMost is building its discovery engine around the GlueSEEKER® platform, designed to identify molecular glues and other degrader molecules capable of addressing ‘undruggable’ targets in oncology and infl ammation. Gilbert’s addition comes at a time when the degrader fi eld is seeing growing validation and investment, with molecular glues increasingly viewed as one of the most promising therapeutic frontiers.


“Adam’s track record in turning complex science into market-ready therapeutics speaks for itself,” commented PhoreMost CSO, Dr Christian Dillon. “His perspective will be invaluable as we take our degrader programmes into clinical development.”


Gilbert himself noted the momentum in the space: “Molecular glues hold enormous potential to reshape drug discovery. PhoreMost’s approach to systematically uncovering these opportunities is exciting, and I look forward to helping translate that science into medicines with real patient impact.”


More information online: ilmt.co/PL/QpZD 65562pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60